Novo Nordisk

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its annual sales forecast on Wednesday, citing a decline in its US market share. Novo Nordisk blamed the revised outlook...

China has authorized the use of Novo Nordisk’s well-known weight-loss medication Wegovy, the Danish pharmaceutical behemoth announced. Beijing has approved the ground-breaking treatment for those who are overweight or obese and have at least one weight-related...

Novo Nordisk notched a win on Monday in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent, a key manufacturing subcontractor of the product, for...

Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable company, said Wednesday its net profit soared by 51 percent last year, driven by sales of its popular diabetes and obesity drugs. Novo Nordisk reported a net profit...

Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 20231 to expand the existing production site in Chartres, France, for the current and future product portfolio within...

Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a...

Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and data science capabilities. Through the partnership, Microsoft is providing...

Novo Nordisk A/S and the University of Toronto (U of T) has announced a DKK 200 million (CAD 40 million) investment to establish the Novo Nordisk Network for Healthy Populations. The network will focus on new...

Novo Nordisk announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first...

Novo Nordisk A/S declared that it’s entered into a definitive deal to buy Corvidia Therapeutics Inc., a privately held, clinical stage company which is focused on the research and development of transformative therapies for cardio-renal diseases....